Last reviewed · How we verify

Pfizer-BioNTech COVID-19 mRNA vaccine

Pfizer · FDA-approved active Biologic Quality 38/100

mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response

The Pfizer-BioNTech COVID-19 mRNA vaccine holds a dominant market position as one of the world's leading vaccines, with 81 approved indications and significant global revenue. Its competitive advantage lies in its high efficacy rate of 95% and relatively simpler storage conditions compared to other mRNA vaccines. A key risk is the lack of ongoing clinical trials, which may limit future regulatory approvals and market expansion. The pipeline outlook remains robust, supported by the vaccine's strong performance and potential for additional indications requiring PD-L1 companion diagnostics.

At a glance

Generic namePfizer-BioNTech COVID-19 mRNA vaccine
Also known asPfizer-BioNTech COVID-19 Vaccine
SponsorPfizer
Drug classvaccine
TargetSARS-CoV-2
ModalityBiologic
Therapeutic areaImmunology
PhaseFDA-approved

Mechanism of action

The Pfizer-BioNTech COVID-19 mRNA vaccine works by introducing a piece of genetic material called messenger RNA (mRNA) into the body. This mRNA instructs the cells to produce a protein that is similar to the COVID-19 virus. The immune system recognizes this protein as foreign and mounts a response to it, providing immunity against COVID-19. This approach is novel because it uses genetic material to stimulate an immune response, rather than using a weakened or killed virus.

Approved indications

Common side effects

No common side effects on file.

Drug interactions

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: